



Clinical trial results: Continued Access to Darunavir/ritonavir (DRV/rtv) in HIV-1 Infected Adults, Adolescents and Children Aged 3 Years and Above Summary

EudraCT number	2017-000285-30
Trial protocol	Outside EU/EEA
Global end of trial date	29 June 2021

Results information

Result version number	v1 (current)
This version publication date	15 July 2022
First version publication date	15 July 2022

Trial information

Trial identification

Sponsor protocol code	TMC114IFD3001
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01281813
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Janssen Research & Development, LLC
Sponsor organisation address	920, US Highway, Route 202, South Raritan, United States, 08869
Public contact	Clinical Registry Group, Janssen Research & Development, LLC, clinicaltrialsEU@its.jnj.com
Scientific contact	Clinical Registry Group, Janssen Research & Development, LLC, clinicaltrialsEU@its.jnj.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	29 June 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	29 June 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial was to continue the provision of DRV/rtv to adult and pediatric subjects who previously received DRV/rtv in the adult (parent) studies C211 (2005-002486-36), C214 (2005-000594-22) , C229 (2007-001939-61) or in the pediatric (parent) Study trial TMC114-TiDP29-C232 (2009-017013-29) and who continued to benefit from the use of DRV/rtv, in countries where DRV was not commercially available for the subject, was not reimbursed, or could not be accessed through another source (example; access program, governmental program).

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practices and applicable regulatory requirements. The safety evaluations included monitoring of adverse events, non-serious adverse events, serious adverse events, clinical laboratory tests, vital signs, electrocardiogram and physical examinations.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	08 August 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Brazil: 1
Country: Number of subjects enrolled	Costa Rica: 7
Country: Number of subjects enrolled	Guatemala: 4
Country: Number of subjects enrolled	Malaysia: 3
Country: Number of subjects enrolled	Panama: 8
Country: Number of subjects enrolled	Thailand: 13
Country: Number of subjects enrolled	Ukraine: 3
Country: Number of subjects enrolled	South Africa: 106
Worldwide total number of subjects	145
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
----------	---

Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	4
Adolescents (12-17 years)	3
Adults (18-64 years)	137
From 65 to 84 years	1
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Subjects who had completed treatment with DRV/rtv in adult parent trials TMC114-C211, TMC114-C214, TMC114-TiDP31-C229 or in pediatric (parent) trial TMC114-TiDP29-C232, who continued to benefit from use of DRV/rtv, who live in country where DRV is not accessible participated in this trial.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Children Less than (<)12 years

Arm description:

HIV-1 infected children subjects received darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 28 months).

Arm type	Experimental
Investigational medicinal product name	Darunavir (DRV) 200 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

200 mg orally bid.

Investigational medicinal product name	DRV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral suspension
Routes of administration	Oral use

Dosage and administration details:

DRV 600 mg orally bid

Investigational medicinal product name	rtv 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

rtv 100 mg orally bid.

Investigational medicinal product name	Ritonavir (rtv) 32 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Oral solution
Routes of administration	Oral use

Dosage and administration details:

rtv 32 mg orally bid.

Arm title	Adolescents (12-17 years)
------------------	---------------------------

Arm description:

HIV-1 infected adolescent subjects received DRV 200 to 600 milligrams (mg) as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 39 months).

Arm type	Experimental
Investigational medicinal product name	DRV 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

DRV 800 mg (2 tablets of 400 mg) orally qd.

Investigational medicinal product name	rtv 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

rtv 100 mg tablets orally qd.

Arm title	Adults (greater than or equal to [$\geq$] 18 years)
------------------	---

Arm description:

HIV-1 infected adult subjects received DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet and/or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (maximum exposure duration: up to 105 months).

Arm type	Experimental
Investigational medicinal product name	DRV 800 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

DRV 800 mg (2 tablets of 400 mg) orally qd.

Investigational medicinal product name	rtv 100 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

rtv 100 mg tablet BID.

Investigational medicinal product name	DRV 600 mg
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

DRV 600 mg tablet orally BID.

Number of subjects in period 1	Children Less than (<)12 years	Adolescents (12-17 years)	Adults (greater than or equal to [>=] 18 years)
Started	4	4	137
Completed	0	0	0
Not completed	4	4	137
Subject Reached A Virologic Endpoint	-	-	5
Consent withdrawn by subject	-	-	13
Sponsor's Decision	4	3	7
Adverse event, non-fatal	-	-	10
Subject Non-Compliant	-	-	6
Lost to follow-up	-	-	31
Switched to Commercially Available Medication	-	-	26
unspecified	-	1	39

Baseline characteristics

Reporting groups

Reporting group title	Children Less than (<)12 years
Reporting group description: HIV-1 infected children subjects received darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 28 months).	
Reporting group title	Adolescents (12-17 years)
Reporting group description: HIV-1 infected adolescent subjects received DRV 200 to 600 milligrams (mg) as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 39 months).	
Reporting group title	Adults (greater than or equal to [$\geq$] 18 years)
Reporting group description: HIV-1 infected adult subjects received DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet and/or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (maximum exposure duration: up to 105 months).	

Reporting group values	Children Less than (<)12 years	Adolescents (12-17 years)	Adults (greater than or equal to [$\geq$] 18 years)
Number of subjects	4	4	137
Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	4	0	0
Adolescents (12-17 years)	0	3	0
Adults (18-64 years)	0	1	136
From 65-84 years	0	0	1
85 years and over	0	0	0
Age continuous Units: years			
arithmetic mean	11	13.8	41.5
standard deviation	± 0	± 2.87	± 8.6
Sex: Female, Male Units: subjects			
Female	1	2	82
Male	3	2	55
Race/Ethnicity, Customised Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	0	0	18
Black or African American	4	4	91
Native Hawaiian or Other Pacific Islander	0	0	0
White	0	0	6
More than one race	0	0	0

Unknown or Not Reported	0	0	0
Hispanic	0	0	18
Other	0	0	4
Region of Enrollment Units: Subjects			
BRAZIL	0	1	0
COSTA RICA	0	0	7
GUATEMALA	0	0	4
MALAYSIA	0	0	3
PANAMA	0	0	8
SOUTH AFRICA	4	3	99
THAILAND	0	0	13
UKRAINE	0	0	3

Reporting group values	Total		
Number of subjects	145		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	4		
Adolescents (12-17 years)	3		
Adults (18-64 years)	137		
From 65-84 years	1		
85 years and over	0		
Age continuous Units: years			
arithmetic mean			
standard deviation	-		
Sex: Female, Male Units: subjects			
Female	85		
Male	60		
Race/Ethnicity, Customised Units: Subjects			
American Indian or Alaska Native	0		
Asian	18		
Black or African American	99		
Native Hawaiian or Other Pacific Islander	0		
White	6		
More than one race	0		
Unknown or Not Reported	0		
Hispanic	18		
Other	4		
Region of Enrollment Units: Subjects			
BRAZIL	1		

COSTA RICA	7		
GUATEMALA	4		
MALAYSIA	3		
PANAMA	8		
SOUTH AFRICA	106		
THAILAND	13		
UKRAINE	3		

End points

End points reporting groups

Reporting group title	Children Less than (<)12 years
Reporting group description: HIV-1 infected children subjects received darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 28 months).	
Reporting group title	Adolescents (12-17 years)
Reporting group description: HIV-1 infected adolescent subjects received DRV 200 to 600 milligrams (mg) as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 39 months).	
Reporting group title	Adults (greater than or equal to [$\geq$] 18 years)
Reporting group description: HIV-1 infected adult subjects received DRV 800 mg (2 tablets of 400 mg) orally every day (qd) along with rtv 100 mg tablet and/or DRV 600 mg tablet orally BID along with rtv 100 mg tablet (maximum exposure duration: up to 105 months).	

Primary: Number of Subjects with Serious Adverse Events

End point title	Number of Subjects with Serious Adverse Events ^[1]
End point description: Adverse events (AEs) were defined as any untoward medical occurrence (any unfavorable and unintended sign [including an abnormal laboratory finding], symptom, or disease) that occurred in a subject or clinical investigation subjects administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. Serious adverse events (SAEs) were defined as any untoward medical occurrence that at any dose: resulted in death; was life threatening; required inpatient hospitalisation or prolongation of existing hospitalisation; resulted in persistent or significant disability/incapacity; or was a congenital anomaly/birth defect. Full analysis set (FAS) included all subjects who had taken at least one dose of DRV, regardless of their compliance with the protocol and adherence to the dose regimen.	
End point type	Primary
End point timeframe: Up to 9 years 11 months	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: Descriptive statistics was done, no inferential statistical analysis was performed	

End point values	Children Less than (<)12 years	Adolescents (12-17 years)	Adults (greater than or equal to [$\geq$] 18 years)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	4	137	
Units: subjects	0	1	26	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects with Adverse Events Leading to Study Drug Discontinuation

End point title	Number of Subjects with Adverse Events Leading to Study Drug Discontinuation ^[2]
-----------------	---

End point description:

The AEs were defined as any untoward medical occurrence (any unfavorable and unintended sign [including an abnormal laboratory finding], symptom, or disease) that occurred in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. FAS included all subjects who had taken at least one dose of DRV, regardless of their compliance with the protocol and adherence to the dose regimen.

End point type	Primary
----------------	---------

End point timeframe:

Up to 9 years 11 months

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed

End point values	Children Less than (<)12 years	Adolescents (12-17 years)	Adults (greater than or equal to [$\geq$] 18 years)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	4	137	
Units: subjects	0	0	9	

Statistical analyses

No statistical analyses for this end point

Primary: Number of Subjects with Adverse Events Possibly Related to Darunavir/ritonavir (DRV/rtv) Treatment

End point title	Number of Subjects with Adverse Events Possibly Related to Darunavir/ritonavir (DRV/rtv) Treatment ^[3]
-----------------	---

End point description:

Number of subjects with adverse events possibly related to DRV/rtv treatment were reported in this endpoint. FAS included all subjects who had taken at least one dose of DRV, regardless of their compliance with the protocol and adherence to the dose regimen.

End point type	Primary
----------------	---------

End point timeframe:

Up to 9 years 11 months

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Descriptive statistics was done, no inferential statistical analysis was performed

End point values	Children Less than (<)12 years	Adolescents (12-17 years)	Adults (greater than or equal to [$\geq$] 18 years)	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	4	4	137	
Units: subjects	0	0	4	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 9 years 11 months

Adverse event reporting additional description:

Full Analysis Set (FAS) included all subjects who had taken at least one dose of DRV, regardless of their compliance with the protocol and adherence to the dose regimen.

Assessment type	Non-systematic
-----------------	----------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	23.0
--------------------	------

Reporting groups

Reporting group title	Children Less than (<)12 years
-----------------------	--------------------------------

Reporting group description:

HIV-1 infected children subjects received darunavir (DRV) 200 to 600 milligrams (mg) as oral suspension twice daily (BID) along with ritonavir (rtv) 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 28 months).

Reporting group title	Adults (greater than or equal to [$\geq$] 18 years)
-----------------------	---

Reporting group description:

HIV-1 infected adult subjects received DRV 800 mg (2 tablets of 400 mg) orally qd along with rtv 100 mg tablet and/or DRV 600 mg tablet orally twice daily (BID) along with rtv 100 mg tablet (maximum exposure duration: up to 105 months).

Reporting group title	Adolescents (12-17 years)
-----------------------	---------------------------

Reporting group description:

HIV-1 infected adolescent subjects received DRV 200 to 600 milligrams (mg) as oral suspension BID along with rtv 32 to 100 mg as oral solution/suspension BID based on their body weight (maximum exposure duration: up to 39 months)

Serious adverse events	Children Less than (<)12 years	Adults (greater than or equal to [$\geq$] 18 years)	Adolescents (12-17 years)
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 4 (0.00%)	26 / 137 (18.98%)	1 / 4 (25.00%)
number of deaths (all causes)	0	3	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Breast Cancer			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hodgkin's Disease			

subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep Vein Thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Peripheral Ischaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pregnancy, puerperium and perinatal conditions			
Abortion Threatened			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal Death			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Premature Baby			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Premature Labour			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Immature Respiratory System			

subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Psychiatric disorders			
Acute Psychosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Intentional Self-Injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 137 (0.00%)	1 / 4 (25.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Major Depression			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femoral Neck Fracture			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Foetal Exposure During Pregnancy			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Head Injury			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Maternal Exposure During Breast Feeding			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Radius Fracture			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Angina Pectoris			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Headache			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ear and labyrinth disorders			
Deafness Unilateral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Duodenal Ulcer Haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Haemorrhoids			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Vomiting			

subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Hepatobiliary disorders			
Jaundice Cholestatic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	1 / 1	0 / 0
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal Failure			
subjects affected / exposed	0 / 4 (0.00%)	3 / 137 (2.19%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Bone Tuberculosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Breast Abscess			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Groin Abscess			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Infected Cyst			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Malaria			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	2 / 137 (1.46%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Pulmonary Tuberculosis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Sinusitis			
subjects affected / exposed	0 / 4 (0.00%)	1 / 137 (0.73%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary Tract Infection			
subjects affected / exposed	0 / 4 (0.00%)	2 / 137 (1.46%)	0 / 4 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 3	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	Children Less than (<)12 years	Adults (greater than or equal to [$\geq$] 18 years)	Adolescents (12-17 years)
Total subjects affected by non-serious adverse events subjects affected / exposed	0 / 4 (0.00%)	4 / 137 (2.92%)	0 / 4 (0.00%)
Pregnancy, puerperium and perinatal conditions Pregnancy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	4 / 137 (2.92%) 4	0 / 4 (0.00%) 0

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 February 2017	-Clinical study protocol TMC114-TiDP29-C232 was integrated into protocol TMC114IFD3001, to allow subjects enrolled in Study TMC114-TiDP29-C232 to participate in Study TMC114IFD3001. - The name of the sponsor of the study was updated from 'Tibotec Pharmaceuticals' to 'Janssen Research & Development' because of the transition of the Johnson & Johnson Pharmaceutical Research & Development companies to a unified Janssen identity, as of 2 February 2012.
20 June 2019	The amendment was implemented to simplify the follow-up. DRV was approved in 2006 for use in adults and in 2011 for use in children as of the age of 3 years and, by June 2019, had already a well established safety profile. Hence, collection of additional data in Study TMC114IFD3001 was unlikely to provide substantial additional information on DRV or to impact the risk benefit assessment.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported